Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Temozolomide in Advanced Neuroendocrine Tumors
NCT00137774Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2004
- Primary completion
- Jul 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in neuroendocrine tumors (NETs), sponsored by Dana-Farber Cancer Institute. Started Nov 2004; status: completed.
02
Drugs
bevacizumab
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT00137774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00137774.